| Apimeds Pharmaceuticals US, Inc. (APUS) |
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 |
| Balance Sheet Date | | 2026-Mar-31 | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Fiscal Period | | Q1-FY2026 | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Close Price of Common Stock | 1.42$ | 1.73$ | 1.84$ | 1.80$ | 1.76$ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Market Cap of Common Stock | 21,429,471$ | 21,756,451$ | 23,139,809$ | 22,573,889$ | 20,373,730$ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| QoQ% | (1.50%) | (5.98%) | 2.51% | 10.80% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| YoY% | 5.18% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Close Price of Warrant | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Close Price of Unit | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Close Price of Right | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Shares Outstanding | 15,091,177 | 12,575,983 | 12,575,983 | 12,575,983 | 12,575,983 | 3 | 7,903,850 | 7,903,850 | 7,903,850 | 7,903,850 | 7,903,850 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| QoQ% | 20.00% | .00% | .00% | .00% | 483,691,553.85% | (100.00%) | .00% | .00% | .00% | .00% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| YoY% | 20.00% | 483,691,553.85% | 59.11% | 59.11% | 59.11% | (100.00%) | .00% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |